Stocks moved sharply in midday trading as company-specific catalysts drove gains and losses across telecom, healthcare, airlines, and aerospace suppliers, while gold-related momentum supported parts of the mining sector. Shares of major telecom operators slid on competitive concerns linked to SpaceX’s Starlink Mobile rollout, while several healthcare and industrial names surged after regulatory updates, contract developments, or supply signals.
Key takeaways
- Telecom stocks fell as investors weighed intensified competition from SpaceX’s Starlink Mobile service; T-Mobile dropped 13%, while AT&T and Verizon fell about 10% each.
- FDA approval lifted Teva after the U.S. regulator cleared Weltruza, a monthly injectable treatment for adult schizophrenia; Teva shares rose 6%.
- Delta slid on earnings outlook after the airline reported weaker-than-expected third-quarter results and pointed to higher fuel costs; shares fell nearly 2%.
- Optics demand signals boosted Lumentum as the CEO said key optical components are sold out through 2029, despite expected production constraints; shares climbed about 7%.
- Gold supported miners with Freeport-McMoRan gaining 3% as U.S. gold futures rose 1.4% for December delivery.
What drove the biggest moves
Telecoms and the SpaceX factor. Telecom providers were among the steepest decliners after reporting midday indicated heightened competition concerns around SpaceX’s Starlink Mobile service. T-Mobile led the drop, falling 13%, while AT&T and Verizon each slid about 10%. Investors appeared focused on potential pressure to wireless market share and pricing dynamics for legacy carriers as alternative connectivity options expand.
Cell tower operators outperformed. In a potential “beneficiary” reaction, cellular tower companies rallied as the market looked beyond carrier competition to infrastructure demand. Crown Castle rose 12%, SBA Communications gained 6%, and American Tower advanced nearly 8%.
Teva gains on FDA clearance. Teva Pharmaceutical Industries added 6% after the company said the Food and Drug Administration approved Weltruza, its monthly long-acting injectable treatment for schizophrenia in adults. The approval strengthens Teva’s product pipeline and may improve investor expectations for future revenue contributions from its branded portfolio.
Delta Air Lines points to higher fuel costs. Delta Air Lines fell almost 2% following third-quarter results that missed expectations. Delta reported adjusted earnings of $1.72 per share on revenue of $17.59 billion, compared with an LSEG consensus of $1.75 per share on $17.67 billion. The company also attributed its full-year earnings outlook reduction to higher fuel costs, underscoring sensitivity to energy-related input costs as airline pricing and demand normalize.
Lumentum’s supply outlook sparks a jump. Lumentum surged about 7% after CEO Michael Hurlston said the company’s optical components are sold out through 2029. Hurlston also indicated Lumentum will struggle to meet as much as 70% of demand for some products through next year. The combination of long-dated sales visibility and near-term supply constraints helped explain the strong share reaction.
Managed care names react to CMS ratings updates. Managed care providers moved on expectations for Medicare Advantage performance and quality metrics as the Centers for Medicare & Medicaid Services rolled out 2027 Star Ratings on its Medicare Plan Finder ahead of fall open enrollment. Humana climbed 12% after the company’s largest Medicare Advantage contract saw its rating improve, while Alignment Healthcare plunged nearly 14%, reflecting the market’s focus on how star quality ratings can influence enrollment and reimbursement outcomes.
Apple component demand concerns weigh on shares. Apple fell nearly 2% after Nikkei Asia reported the company is cutting component orders for its iPhone 18 Pro amid weaker-than-expected demand. The report also said October production orders for the iPhone 18 Pro and the iPhone 18 Pro Max were reduced by 15% from initial plans. Investors appeared to treat the update as an early signal of demand risk for the premium iPhone lineup.
Archer Aviation gains on analyst coverage. Archer Aviation rose 3% after Barclays assumed coverage with an overweight rating. The bank set a price target of $8, implying about 69% upside from Thursday’s close, a move that likely supported sentiment around the company’s electric vertical takeoff and landing aircraft program.
Other corporate updates also shaped mid-session performance. Avient shares fell more than 7% after CEO Ashish Khandpur stepped down and was replaced by Mike Frank. Park Aerospace dropped 9% after reporting second-quarter results of 21 cents per share on revenue of $20.8 million, versus 12 cents and $16.4 million in the year-ago period. Despite the decline, the stock remained ahead about 25% for 2026. Freeport-McMoRan gained 3% as gold prices climbed.
Market reaction and investor implications
The midday pattern reflected a mix of regulatory, operational, and macro-linked drivers. Telecom declines contrasted with strength in tower operators, suggesting investors are differentiating between competitive pressure on wireless services and the longer-term demand for physical network infrastructure. In healthcare, the FDA approval and CMS Star Ratings updates reinforced how quickly regulatory and reimbursement-related developments can reprice risk for drugmakers and insurers. In airlines and consumer tech, Delta’s guidance cut and Apple’s component-order reductions pointed to demand and cost pressures that could weigh on earnings visibility.
Bigger picture: what investors are watching next
Investors now appear focused on whether supply-and-demand signals persist—particularly for Lumentum’s constrained product categories and for Apple’s premium smartphone demand trajectory—as well as ongoing sensitivity to energy costs for airlines like Delta. For the broader market, continued attention to Medicare Advantage Star Ratings could drive further repricing across managed care, while movements in gold prices may remain a near-term catalyst for miners. Upcoming company earnings, additional guidance updates, and follow-on regulatory and policy developments from the Centers for Medicare & Medicaid Services and the FDA are likely to keep stock reactions elevated.
